Andrew Roberts

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.

Thomas E Lew, Victor S Lin, Edward Robert Scheffer Cliff, Piers Blombery, Ella R Thompson, Sasanka Mithila Handunnetti, David A Westerman, Bryone Jean Kuss, Constantine S Tam, David Ching Siang Huang, John F Seymour, Andrew W Roberts, Mary Ann Anderson

Journal article  |  2021  |  Blood Adv

Covalent Bruton tyrosine kinase inhibitors (BTKis) and the BCL2 inhibitor venetoclax have significantly improved outcomes for pati..

Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.

Matthew S Davids, Andrew W Roberts, Vaishalee P Kenkre, William G Wierda, Abhijeet Kumar, Thomas J Kipps, Michelle Boyer, Ahmed Hamed Salem, John C Pesko, Jennifer A Arzt, Margaret Mantas, Su Y Kim, John F Seymour

Journal article  |  2021  |  Clin Cancer Res

PURPOSE: We previously reported a 44% overall response rate (ORR) with the oral BCL-2 inhibitor venetoclax in a phase I study of r..

Introduction to a review series on small molecule targeted therapies for lymphoid malignancies.

Andrew W Roberts, Freda Kathryn Stevenson

Journal article  |  2021  |  Blood

BCL2 inhibitors and MCL1 inhibitors for hematological malignancies.

Andrew W Roberts, Andrew H Wei, David Ching Siang Huang

Journal article  |  2021  |  Blood

BCL2 and MCL1 are commonly expressed pro-survival (anti-apoptotic) proteins in hematological cancers and play important roles in t..

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, Patricia Walker, Anthony Schwarer, Andrew W Roberts, Philip Campbell, Robin Filshie, Sam Norton, John Reynolds, Mary Young, William Pierceall, Anjan Thakurta, Manman Guo, Udo Oppermann, Maria Wang, Yan Ren, Nola Kennedy, Samir Parekh, Andrew Spencer

Journal article  |  2021  |  LEUKEMIA & LYMPHOMA

LEOPARD was a single arm, phase II study of lenalidomide (LEN) and alternate day prednisolone maintenance in patients with newly d..

Efficacy of venetoclax plus rituximab for relapsed CLL: Five-year follow-up of continuous or limited-duration therapy.

Shuo Ma, John F Seymour, Danielle M Brander, Thomas J Kipps, Michael Y Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W Roberts

Journal article  |  2021  |  Blood

We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocyt..

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Rachel Thijssen, Sarah T Diepstraten, Donia Moujalled, Edward Chew, Christoffer Flensburg, Melissa X Shi, Michael A Dengler, Veronique Litalien, Sarah MacRaild, Maoshan Chen, Natasha S Anstee, Boris Reljic, Sarah S Gabriel, Tirta M Djajawi, Chris D Riffkin, Brandon J Aubrey, Catherine Chang, Lin Tai, Zhen Xu, Thomas Morley, et al.

Journal article  |  2021  |  BLOOD

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemi..

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

Sasanka Handunnetti, Mary Ann Anderson, Andrew W Roberts, Matthew S Davids, Shuo Ma, Michelle Boyer, Jennifer Arzt, Abdullah Al Masud, Relja Popovic, Amanda Jacobson, Su Y Kim, John F Seymour

Journal article  |  2021  |  eJHaem

Opioid Use Disorder and Overdose in Older Adults With Breast, Colorectal, or Prostate Cancer.

Andrew W Roberts, Samantha Eiffert, Elizabeth M Wulff-Burchfield, Stacie B Dusetzina, Devon K Check

Journal article  |  2021  |  J Natl Cancer Inst

BACKGROUND: Despite high rates of opioid therapy, evidence about the risk of preventable opioid harms among cancer survivors is un..

Naloxone Prescribing Among Frequent Opioid Prescribers in Medicare Part D from 2013 to 2017: a Retrospective Study.

Andrew W Roberts

Journal article  |  2021  |  J Gen Intern Med